Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02045433 · ClinicalTrials.gov registry record · Phase 2

Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer

A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.

Terminated
Registry status
Phase 2
Development phase
16
Enrollment target

NCT02045433: Clinical Trial Phase 2 study, sponsored by University of Texas Southwestern Medical Center.

NCT02045433 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02045433, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.

TERMINATED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether SABR boost therapy is effective in women with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI) or genitourinary (GU) toxicity.

Primary Outcome

The primary objective is to improve primary tumor local control of eligible LACC using SABR as the mechanism for delivering boost therapy to 85% at 2 years post treatment

Interventions

  • RADIATION SABR Boost Therapy

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2014-03-27
Est. Completion 2018-11-04
Phase Phase 2

Why NCT02045433 stopped before completion

NCT02045433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 1 intervention - of which SABR Boost Therapy is the first listed.

NCT02045433 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02045433 about?

NCT02045433 is a clinical study titled "Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer". The purpose of this study is to determine whether SABR boost therapy is effective in women with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI) or genitourinary (GU) toxicity.

What is the current status of trial NCT02045433?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2014-03-27. Estimated completion is 2018-11-04.

What interventions are being tested in trial NCT02045433?

The interventions under investigation include: SABR Boost Therapy (RADIATION).

Who is sponsoring clinical trial NCT02045433?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02045433's enrollment target sits among peer trials

16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02045433, the US trial registry maintained by the National Library of Medicine. NCT02045433 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.